potent MAT2A inhibitor in vivo tool

efficacy in MTAP-mut. xenograft (50 mpk SC)

from fragment-based DD (frag. merging)

J. Med. Chem., Apr. 26, 2021

AstraZeneca, Cambridge, UK

The AstraZeneca MAT2a allosteric inhibitor, compound 28, is a remarkably potent (25 nM in cells) in vivo tool compound generated from merging of two weak fragments (Kd = 250 μM…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.